FLGT Jan 2025 22.500 call
| Previous Close | 2.8000 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 22.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 2.8000 - 2.8000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 3 |
Simply Wall St.What Is Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Share Price Doing?
Fulgent Genetics, Inc. ( NASDAQ:FLGT ), is not the largest company out there, but it saw significant share price...
Business WireFulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
EL MONTE, Calif., June 03, 2024--Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, was presented at the American Society for Clinical Oncology (ASCO) Annual Meeting on June 2, 2024 in Chicago, Illinois.
Business WireFulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
EL MONTE, Calif., May 24, 2024--Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting on June 2, 2024 in Chicago, Illinois.
